Anti-rheumatics market to Grow at CAGR 2.9% During 2022 – 2026

anti rheumatic market

Anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026.

PORTLAND, OREGON, UNITED STATES, August 23, 2022 /EINPresswire.com/ -- The demand for anti-rheumatics is on the rise, owing to surge in incidence of rheumatoid arthritis worldwide. Furthermore, surge in geriatric population across the globe is another major factor that fuels the growth of the market.

The global anti-rheumatics market¹ accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6289

Rheumatoid arthritis is an autoimmune disorder, which causes painful and swollen joints in patients. The treatment of this medical condition involves the use of various drugs, known as anti-rheumatics. For instance, different type of drugs involved in the treatment of rheumatoid arthritis include disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, and others. These drugs have different mechanism of action on the medical condition. For instance, DMARDs modify the course of the action and NSAIDs act on the symptoms of the disease such as pain. Furthermore, these drugs are available on prescription and also over-the-counter.

Increase in incidence of rheumatoid arthritis, surge in geriatric population, and rise in incidence of obesity across the world drive the growth of the global anti-rheumatics market. However, side effects related to the medication and higher cost of biologics & biosimilars hinder the growth of the market. On the other hand, R&D activities in the field of biosimilars and novel biologics present numerous opportunities in the market.

Rise in prevalence of rheumatoid arthritis, increase in elderly population, and surge in incidence of obesity worldwide fuel the growth of the global anti-rheumatics market. On the other hand, side effects related to the medication and higher cost of biologics & biosimilars curtail down the growth to certain extent. However, R&D activities in the field of biosimilars and novel biologics are expected to pave the way for multiple opportunities in the industry.

The disease modifying anti-rheumatic drugs (DMARD's)segment to maintain its dominance till 2026-

By on drug class, the disease modifying anti-rheumatics drugs (DMARDs) segment contributed to more than one-third of the total market revenue in 2018, and is anticipated to lead the trail during the study period. The nonsteroidal anti-inflammatory drugs (NSAIDs) segment, on the other hand, is projected to register the fastest CAGR of 3.7% by 2026. The other segments analyzed in the report include corticosteroids and uric acid drugs.

North America to lead in terms of revenue during the forecast period

Based on region, North America held the highest share in 2018, accounting for nearly one-third of the global anti-rheumatics market, and will lead during the forecast period. This is due to easy availability of anti-rheumatics and increase in geriatric population that are susceptible to nephrological disorders. However, Asia-Pacific is estimated to witness the largest growth rate, with a CAGR of 3.7% from 2019 to 2026. This is attributed to increase in healthcare expenditure and surge in awareness of anti-rheumatics.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6289

Key Findings of the Study:

The disease modifying anti-rheumatic drugs segment occupied approximately two-fifth share of the global anti-rheumatics market in 2018.

The nonsteroidal anti-inflammatory drugs segment is anticipated to grow at the highest CAGR throughout the forecast period.

The prescription-based drugs segment accounted for three-fourth share of the market in 2018.

Asia-Pacific is anticipated to grow at the fastest rate during the analysis period, followed by LAMEA

Leading market players

Pfizer, Inc.
Johnson & Johnsons
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Celegene Corporations
MedImmune, LLC
Takeda Pharmaceutical Company Ltd.
Biogen Inc.
Celltrion Inc.
Amgen Inc.

We also Offers Regional and Country Reports-

Japan Anti-Rheumatics Market
South Korea Anti-Rheumatics Market
Singapore Anti-Rheumatics Market
China Anti-Rheumatics Market
Indonesia Anti-Rheumatics Market
Australia Anti-Rheumatics Market
Taiwan Anti-Rheumatics Market

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

¹ https://www.alliedmarketresearch.com/anti-rheumatics-market